Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic NK Cells in Advanced HCC
NCT04162158Phase 2
Key facts
- Status
- Unknown
- Start
- Mar 2019
- Primary completion
- Oct 2022
- Countries
- 1
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Drugs
- AlloNK
- Conditions
- hepatocellular carcinoma (HCC)
01
Overview
Phase 2, open-label trial of AlloNK in hepatocellular carcinoma (HCC) (2 arms), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoints: Incidence of Adverse Events at 2 years and Overall Survival at 2 years. Status: unknown.
02
Design
2 arms- Study design
- Non-randomizedOpen-label
Experimental Arm
Allogeneic NK cells + Targeted Drug
Control Arm
Targeted Drug alone
03
Who it enrols
Patients with advanced HCC (BCLC C), Child-Pugh A/B (5-9), ECOG PS 0-1, and adequate organ function. Must have a suitable donor.
04
Endpoints
Primary
Incidence of Adverse Events
Overall Survival
Secondary
Disease Control Rate
Beyond the preview
Go deeper on NCT04162158.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04162158.